Drug Approval | November 09, 2024
Lupin receives tentative approval from USFDA for Raltegravir Tablets
This product will be manufactured at Lupin’s Nagpur facility in India
This product will be manufactured at Lupin’s Nagpur facility in India
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
The robotic surgery program has continually pushed the boundaries of medical technology
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Subscribe To Our Newsletter & Stay Updated
